Christopher M Booth

Summary

Affiliation: Queen's University
Country: Canada

Publications

  1. doi request reprint Time to adjuvant chemotherapy and survival in non-small cell lung cancer: a population-based study
    Christopher M Booth
    Division of Cancer Care and Epidemiology, Queen s University Cancer Research Institute, Kingston, Canada
    Cancer 119:1243-50. 2013
  2. doi request reprint Adjuvant chemotherapy for non-small cell lung cancer: practice patterns and outcomes in the general population of Ontario, Canada
    Christopher M Booth
    Division of Cancer Care and Epidemiology, Queen s University Cancer Research Institute, Kingston, Canada
    J Thorac Oncol 7:559-66. 2012
  3. doi request reprint Randomised controlled trials in oncology closed early for benefit: trends in methodology, results, and interpretation
    Christopher M Booth
    NCIC Clinical Trials Group and Queen s University Cancer Research Institute, Kingston, Canada
    Eur J Cancer 47:854-63. 2011
  4. doi request reprint Evaluating patient-centered outcomes in the randomized controlled trial and beyond: informing the future with lessons from the past
    Christopher M Booth
    Queen s University Cancer Research Institute, Kingston, Canada
    Clin Cancer Res 16:5963-71. 2010
  5. doi request reprint The impact of socioeconomic status on stage of cancer at diagnosis and survival: a population-based study in Ontario, Canada
    Christopher M Booth
    Division of Cancer Care and Epidemiology, Queen s University Cancer Research Institute, Kingston, Ontario, Canada
    Cancer 116:4160-7. 2010
  6. pmc Adoption of adjuvant chemotherapy for non-small-cell lung cancer: a population-based outcomes study
    Christopher M Booth
    Division of Cancer Care and Epidemiology, Queen s University Cancer Research Institute, 10 Stuart St, Kingston, Ontario K7L 3N6, Canada
    J Clin Oncol 28:3472-8. 2010
  7. doi request reprint Presentation of nonfinal results of randomized controlled trials at major oncology meetings
    Christopher M Booth
    National Cancer Institute of Canada Clinical Trials Group, Cancer Research Institute, Queen s University, Kingston, ON, Canada
    J Clin Oncol 27:3938-44. 2009
  8. doi request reprint Translating new medical therapies into societal benefit: the role of population-based outcome studies
    Christopher M Booth
    Division of Cancer Care and Epidemiology, Queen s University, Kingston, Ontario, Canada
    JAMA 300:2177-9. 2008
  9. ncbi request reprint Endpoints and other considerations in phase I studies of targeted anticancer therapy: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT)
    Christopher M Booth
    National Cancer Institute of Canada Clinical Trials Group, Kingston, ON, Canada
    Eur J Cancer 44:19-24. 2008
  10. pmc Evolution of the randomized controlled trial in oncology over three decades
    Christopher M Booth
    National Cancer Institute of Canada Clinical Trials Group, Queen s University, Kingston, Ontario, Canada
    J Clin Oncol 26:5458-64. 2008

Collaborators

Detail Information

Publications18

  1. doi request reprint Time to adjuvant chemotherapy and survival in non-small cell lung cancer: a population-based study
    Christopher M Booth
    Division of Cancer Care and Epidemiology, Queen s University Cancer Research Institute, Kingston, Canada
    Cancer 119:1243-50. 2013
    ..This is the first report describing the association between time to adjuvant chemotherapy (TTAC) and survival in non-small cell lung cancer (NSCLC)...
  2. doi request reprint Adjuvant chemotherapy for non-small cell lung cancer: practice patterns and outcomes in the general population of Ontario, Canada
    Christopher M Booth
    Division of Cancer Care and Epidemiology, Queen s University Cancer Research Institute, Kingston, Canada
    J Thorac Oncol 7:559-66. 2012
    ..Herein, we describe chemotherapy regimens used, dose modifications, survival, and treatment-related toxicity in the general population...
  3. doi request reprint Randomised controlled trials in oncology closed early for benefit: trends in methodology, results, and interpretation
    Christopher M Booth
    NCIC Clinical Trials Group and Queen s University Cancer Research Institute, Kingston, Canada
    Eur J Cancer 47:854-63. 2011
    ..To assess methodology, results and interpretation of oncology randomised controlled trials closed early for benefit (RCTCEB)...
  4. doi request reprint Evaluating patient-centered outcomes in the randomized controlled trial and beyond: informing the future with lessons from the past
    Christopher M Booth
    Queen s University Cancer Research Institute, Kingston, Canada
    Clin Cancer Res 16:5963-71. 2010
    ....
  5. doi request reprint The impact of socioeconomic status on stage of cancer at diagnosis and survival: a population-based study in Ontario, Canada
    Christopher M Booth
    Division of Cancer Care and Epidemiology, Queen s University Cancer Research Institute, Kingston, Ontario, Canada
    Cancer 116:4160-7. 2010
    ..Lower socioeconomic status (SES) is associated with worsened cancer survival. The authors evaluate the impact of SES on stage of cancer at diagnosis and survival in Ontario, Canada...
  6. pmc Adoption of adjuvant chemotherapy for non-small-cell lung cancer: a population-based outcomes study
    Christopher M Booth
    Division of Cancer Care and Epidemiology, Queen s University Cancer Research Institute, 10 Stuart St, Kingston, Ontario K7L 3N6, Canada
    J Clin Oncol 28:3472-8. 2010
    ..Here, we evaluate the uptake of ACT and its impact on outcomes in the general population of Ontario, Canada...
  7. doi request reprint Presentation of nonfinal results of randomized controlled trials at major oncology meetings
    Christopher M Booth
    National Cancer Institute of Canada Clinical Trials Group, Cancer Research Institute, Queen s University, Kingston, ON, Canada
    J Clin Oncol 27:3938-44. 2009
    ..To assess the frequency, implications, and factors associated with reporting nonfinal analyses (NFAs) of randomized controlled trials (RCTs) as abstract publications...
  8. doi request reprint Translating new medical therapies into societal benefit: the role of population-based outcome studies
    Christopher M Booth
    Division of Cancer Care and Epidemiology, Queen s University, Kingston, Ontario, Canada
    JAMA 300:2177-9. 2008
  9. ncbi request reprint Endpoints and other considerations in phase I studies of targeted anticancer therapy: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT)
    Christopher M Booth
    National Cancer Institute of Canada Clinical Trials Group, Kingston, ON, Canada
    Eur J Cancer 44:19-24. 2008
    ..This report summarises the scientific reviews and discussions as well as the recommendations regarding phase I trial design formulated by the MDICT task force...
  10. pmc Evolution of the randomized controlled trial in oncology over three decades
    Christopher M Booth
    National Cancer Institute of Canada Clinical Trials Group, Queen s University, Kingston, Ontario, Canada
    J Clin Oncol 26:5458-64. 2008
    ..The randomized controlled trial (RCT) is the gold standard for establishing new therapies in clinical oncology. Here we document changes with time in design, sponsorship, and outcomes of oncology RCTs...
  11. doi request reprint Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: a systematic review and meta-analysis
    James J Biagi
    Department of Oncology, Queen s University, Kingston, Ontario, Canada
    JAMA 305:2335-42. 2011
    ..Adjuvant chemotherapy (AC) improves survival among patients with resected colorectal cancer. However, the optimal timing from surgery to initiation of AC is unknown...
  12. pmc External influences and priority-setting for anti-cancer agents: a case study of media coverage in adjuvant trastuzumab for breast cancer
    Christopher M Booth
    National Cancer Institute of Canada Clinical Trials Group, Queen s University, Kingston, Canada
    BMC Cancer 7:110. 2007
    ..In this paper we review external factors that may influence decision-making bodies and present a case study of media response in Ontario, Canada to adjuvant trastuzumab for breast cancer...
  13. ncbi request reprint Reflections on medical oncology: 25 years of clinical trials--where have we come and where are we going?
    Christopher M Booth
    National Cancer Institute of Canada Clinical Trials Group, Queen s University, Kingston, Ontario, Canada
    J Clin Oncol 26:6-8. 2008
  14. ncbi request reprint Adjuvant chemotherapy for resected non-small cell lung cancer
    Christopher M Booth
    Department of Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada
    J Thorac Oncol 1:180-7. 2006
    ..In this review, we describe early adjuvant trials and highlight the recent landmark studies in this disease. The focus of ongoing and future research efforts is also discussed...
  15. doi request reprint Clinical benefit in oncology trials: is this a patient-centred or tumour-centred end-point?
    Pavlo Ohorodnyk
    NCIC Clinical Trials Group, Queen s University, Kingston, ON, Canada
    Eur J Cancer 45:2249-52. 2009
    ..In the trial by Burris et al. CB was a composite measure of pain, performance status and weight. Here we describe how CB has been used in oncology trials since that time...
  16. ncbi request reprint Discordance between conclusions stated in the abstract and conclusions in the article: analysis of published randomized controlled trials of systemic therapy in lung cancer
    Abdullah K Altwairgi
    Cancer Center of Southeastern Ontario, Queen s University, 25 King St West, Kingston, Ontario, Canada
    J Clin Oncol 30:3552-7. 2012
    ..However, discordances have been noticed in summary conclusions in the abstracts and the main body of some articles. This article evaluated such discordances in detail...
  17. ncbi request reprint Design and conduct of phase II studies of targeted anticancer therapy: recommendations from the task force on methodology for the development of innovative cancer therapies (MDICT)
    Christopher M Booth
    National Cancer Institute of Canada Clinical Trials Group, Queen s University, Kingston, ON, Canada
    Eur J Cancer 44:25-9. 2008
    ..The MDICT cautioned on the use of small randomised trials which have a number of statistical pitfalls and dangers and strongly encouraged the complete reporting, including negative trials, in the scientific literature...
  18. ncbi request reprint Rotation to methadone after opioid dose escalation: How should individualization of dosing occur?
    Camilla Zimmermann
    Department of Psychosocial Oncology and Palliative Care, Princess Margaret Hospital, Toronto, ON, Canada, M5G 2M9
    J Pain Palliat Care Pharmacother 19:25-31. 2005
    ..A possible conversion method for rotation to methadone for patients with escalating pain and opioid use is suggested...